查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1552951

癌胚抗原市场规模、份额、趋势分析报告：按类型、性别、产品、测试、最终用途、地区和细分市场预测，2024-2030 年

Carcinoembryonic Antigen Market Size, Share & Trends Analysis Report By Type (Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer), By Gender, By Product, By Test, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格
简介目录

癌胚抗原市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球癌胚抗原市场规模将达到29.5亿美元，2024年至2030年复合年增长率为5.5%。

可与其他生物标记结合使用的新型生物标记开发的持续技术进步预计将在预测期内提高利用率。此外，癌症盛行率的增加预计将增加对有效诊断工具的需求。根据世界卫生组织估计，2012年全球癌症患者人数约1,410万，其中女性670万，男性740万。对微创诊断方法的需求不断增长预计也将在决定市场成长方面发挥重要作用。微创诊断程序的主要优点包括由于切口较小而提高患者满意度。此外，这些手术由于住院时间相对较短且术后併发症较少，因此在经济上是可行的。

癌胚抗原市场报告亮点：

  • 大肠直肠癌是软骨胚胎抗原市场收益最高的应用领域之一，预计2023年将达到1.9332亿美元。大肠直肠癌盛行率的不断增加以及各个阶段癌胚抗原检测的使用是占很大比例的重要因素之一。例如，2012年，美国大肠直肠癌新患者估计超过93,000例，仅结直肠癌死亡人数估计就超过49,700例。
  • 基于癌胚抗原的乳癌诊断被认为是市场上最有利可图的应用领域。该市场将受到50岁以上女性人口增加、荷尔蒙补充疗法（HRT）和整容手术需求增加等因素的推动。此外，意识层级的提高和政府有利倡议的存在预计将提高预测期内的治疗率。
  • 由于发病率高、报销框架良好、消费者意识层级高以及医疗保健支出水平相对较高，北美将在 2023 年成为最大的区域市场。
  • 预计亚太地区将在预测期内出现最有利的成长。开拓的机会的存在、医疗基础设施的不断改善、经济发展以及意识层级的提高是促成这一快速增长的因素。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章癌胚抗原市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌胚抗原市场分析工具
    • 波特的分析
    • PESTEL分析

第四章癌胚抗原市场：按类型估计和趋势分析

  • 细分仪表板
  • 癌胚抗原市场：2023年和2030年按类型分類的变化分析
  • 大肠直肠癌
  • 胰臟癌
  • 卵巢癌
  • 乳癌
  • 甲状腺癌
  • 其他的

第五章癌胚抗原市场：性别估计与趋势分析

  • 细分仪表板
  • 癌胚抗原市场：性别差异分析，2023 年和 2030 年
  • 男性
  • 女士

第六章癌胚抗原市场：依产品估计与趋势分析

  • 细分仪表板
  • 癌胚抗原市场：2023 年和 2030 年按产品分類的变化分析
  • CD66a
  • CD66b
  • CD66c
  • CD66d
  • CD66f

第七章癌胚抗原市场：测试估计和趋势分析

  • 细分仪表板
  • 癌胚抗原市场：2023 年和 2030 年测试变化分析
  • 分子检测
  • 血清检测

第 8 章癌胚抗原市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 癌胚抗原市场：2023 年和 2030 年最终用途的变化分析
  • 医院
  • 研究所
  • 其他的

第九章癌胚抗原市场：区域估计和趋势分析

  • 2023 年及 2030 年癌胚抗原市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Quest Diagnostics Incorporated
    • F. Hoffmann-La Roche Ltd
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • Abbott
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Omega Diagnostics Ltd
    • Boster Biological Technology
    • Lee BioSolutions
简介目录
Product Code: 978-1-68038-425-3

Carcinoembryonic Antigen Market Growth & Trends:

The global carcinoembryonic antigen market size is expected to reach USD 2.95 billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Constant technological advancements pertaining to the development of novel biomarkers which can be used in combination with other biomarkers is expected to boost usage rates over the forecast period. Furthermore, the increasing prevalence of cancer is expected to heighten the demand for effective diagnostic tools. According to the WHO estimates in 2012, global cancer incidences were nearly 14.1 million, which include 6.7 million female patients and 7.4 million male patients. Increasing demand for minimally invasive diagnostics procedures is also expected to play a vital role in determining market growth. Key advantages associated with minimally invasive diagnostics procedures include elevated patient satisfaction levels as they entail minor incision wounds. In addition, these procedures involve relatively lesser hospital stays and therefore, are economically viable and involve fewer post procedure complications.

Carcinoembryonic Antigen Market Report Highlights:

  • Colorectal cancer was one of the largest revenue generating application segment of the carcinoembryonic antigen market and was estimated at USD 193.32 million in 2023. Increasing prevalence of colorectal cancer and usage of carcinoembryonic antigen tests at various stages is one of the critical factors accounting for its large share. For instance, in 2012, new cases of colorectal cancer were estimated to be over 93,000 and death due to colorectal cancer is expected to be over 49,700 in the U.S alone.
  • Carcinoembryonic antigen based breast cancer diagnosis is identified as the most lucrative application segment of the market. The market is driven by factors such as growing number of female population above 50 years, growing demand for Hormone Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient awareness levels and the presence of favorable government initiatives are expected to improve treatment rates over the forecast period.
  • North America was the largest regional market in 2023 owing to, the presence of high incidence rates, presence of favorable reimbursement framework, and high consumer awareness levels coupled with relatively higher healthcare expenditure levels.
  • Asia Pacific is anticipated to witness the most lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and improving patient awareness levels are some factors accounting for this rapid growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Carcinoembryonic Antigen Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Carcinoembryonic Antigen Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Carcinoembryonic Antigen Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Carcinoembryonic Antigen Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Colorectal Cancer
    • 4.3.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Pancreatic Cancer
    • 4.4.1. Pancreatic Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Ovarian Cancer
    • 4.5.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Thyroid Cancer
    • 4.7.1. Thyroid Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carcinoembryonic Antigen Market: Gender Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Carcinoembryonic Antigen Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Male
    • 5.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Female
    • 5.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carcinoembryonic Antigen Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Carcinoembryonic Antigen Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. CD66a
    • 6.3.1. CD66a Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CD66b
    • 6.4.1. CD66b Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CD66c
    • 6.5.1. CD66c Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CD66d
    • 6.6.1. CD66d Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. CD66f
    • 6.7.1. CD66f Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carcinoembryonic Antigen Market: Test Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Carcinoembryonic Antigen Market: Test Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Molecular Tests
    • 7.3.1. Molecular Tests Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Serology Tests
    • 7.4.1. Serology Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Carcinoembryonic Antigen Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Carcinoembryonic Antigen Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 8.3. Hospitals
    • 8.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Laboratories
    • 8.4.1. Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Others
    • 8.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Carcinoembryonic Antigen Market: Regional Estimates & Trend Analysis

  • 9.1. Carcinoembryonic Antigen Market Share, By Region, 2023 & 2030 (USD Million)
  • 9.2. North America
    • 9.2.1. North America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. China Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Japan Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Australia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Saudi Arabia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. Quest Diagnostics Incorporated
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. F. Hoffmann-La Roche Ltd
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Creative Diagnostics
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Aviva Systems Biology Corporation
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. Abbott
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Laboratory Corporation of America Holdings
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. Merck KGaA
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Omega Diagnostics Ltd
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives
    • 10.4.9. Boster Biological Technology
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments/ Strategic Initiatives
    • 10.4.10. Lee BioSolutions
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments/ Strategic Initiatives